TGFB1 and neoplasm: Importantly, only the combination of RT with anti-TGFβ, but not each treatment alone, induced the T cell-mediated rejection of the irradiated tumor and non-irradiated metastases in mice, indicating that blocking TGFβ unleashes the potential of RT to generate an in situ tumor vaccine [77].